Tumor Size Is Not Everything: Advancing Radiomics as a Precision Medicine Biomarker in Oncology Drug Development and Clinical Care. A Report of a Multidisciplinary Workshop Coordinated by the RECIST Working Group

被引:3
|
作者
Nakajima, Erica C. [1 ]
Simpson, Amber [2 ]
Bogaerts, Jan [3 ]
de Vries, Elisabeth G. E. [4 ]
Do, Richard [5 ]
Garalda, Elena [6 ]
Goldmacher, Greg [7 ]
Kinahan, Paul E. [8 ]
Lambin, Philippe [9 ]
LeStage, Barbara [10 ]
Li, Qin [11 ]
Lin, Frank [12 ]
Litiere, Saskia [3 ]
Perez-Lopez, Raquel [6 ]
Petrick, Nicholas [13 ]
Schwartz, Lawrence [5 ]
Seymour, Lesley [14 ]
Shankar, Lalitha [15 ]
Laurie, Scott A. [16 ]
机构
[1] AstraZeneca, Gaithersburg, MD USA
[2] Queens Univ, Kingston, ON, Canada
[3] EORTC, Brussels, Belgium
[4] Univ Med Ctr Groningen, Groningen, Netherlands
[5] Mem Sloan Kettering Canc Ctr, New York, NY USA
[6] Vall dHebron Inst Oncol, Barcelona, Spain
[7] Merck, Rahway, NJ USA
[8] Univ Washington, Seattle, WA USA
[9] Maastricht Univ, Maastricht, Netherlands
[10] Canc Res Advocate, Wrentham, MA USA
[11] AstraZeneca, Waltham, MA USA
[12] Univ Sydney, Sydney, Australia
[13] US FDA, Silver Spring, MD USA
[14] Queens Univ, Canadian Canc Trials Grp, Kingston, ON, Canada
[15] NCI, NIH, Bethesda, MD USA
[16] Univ Ottawa, Ottawa Hosp Canc Ctr, Ottawa, ON, Canada
关键词
RESPONSE EVALUATION CRITERIA; BONE METASTASES; CANCER; GUIDELINES; INHIBITORS; TRIALS; IMAGES;
D O I
10.1200/PO.23.00687
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Radiomics, the science of extracting quantifiable data from routine medical images, is a powerful tool that has many potential applications in oncology. The Response Evaluation Criteria in Solid Tumors Working Group (RWG) held a workshop in May 2022, which brought together various stakeholders to discuss the potential role of radiomics in oncology drug development and clinical trials, particularly with respect to response assessment. This article summarizes the results of that workshop, reviewing radiomics for the practicing oncologist and highlighting the work that needs to be done to move forward the incorporation of radiomics into clinical trials. This paper by the RECIST Working Group outlines a path to realize the potential of radiomics as a precision biomarker.
引用
收藏
页数:8